Piezo Therapeutics has registered a first-in-human trial of PIEZO-101, a plasmid DNA biostimulator designed to drive extracellular matrix protein expression in aging skin, marking the clinical debut of a delivery platform spun out of Georgia Institute of Technology. The study is notable for combining a nucleic acid therapeutic payload with an investigational electroporation device — the Piezopen — in a non-oncology aesthetic indication, a setting where DNA-based approaches have not previously reached human trials.
The Phase I open-label study (NCT07671027) will enroll up to eight healthy women aged 40 to 65 with visible skin laxity or wrinkling in the knee and décolleté areas. Two dose cohorts are planned, each receiving four intradermal injections of PIEZO-101 followed immediately by Piezopen electroporation at both the knee and décolleté on Day 0 and Day 28. A saline comparator is injected at the same knee sites within each participant, enabling a within-person controlled assessment of local tissue responses. The study is expected to begin in September 2026 and complete by August 2027, according to the trial record. Primary endpoints focus on safety and tolerability through Day 90, while secondary measures include procedural pain scoring for the electroporation step, characterization of local tissue responses such as erythema and edema, and quantification of transgene mRNA expression in knee biopsies by qPCR at seven days after each dose.
A platform built on piezoelectric delivery
The mechanism separates PIEZO-101 from conventional biostimulators such as poly-L-lactic acid or calcium hydroxylapatite fillers, which work through mechanical scaffold effects or non-specific fibroblast stimulation. PIEZO-101 instead encodes a transgene — the specific protein has not been publicly disclosed — intended to restore dermal protein expression that declines with age. After intradermal injection, the Piezopen applies high-voltage pulses through microneedle electrodes, transiently permeabilizing cell membranes to drive plasmid uptake into dermal cells. The cells then transcribe the plasmid and produce the encoded protein locally. The company describes this as enabling "in situ production of therapeutic proteins" without lipid nanoparticles or viral vectors.